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Herceptin, HER2-targeted monoclonal antibody, is one
of the main treatments for breast cancer. However, the
majority of patients that initially respond to Herceptin
begin to progress again within 1 year. Thus, it is very
important to clarify how to overcome resistance as
much as to identify breast cancer patients who will be
benefit from Herceptin. We previously reported that
HSP27 can interact with Her2 protein, and up-regulated
HSP27 may cause Herceptin resistance by increasing
Her2 protein stability in human breast cancer cell line
SK-BR-3 with induced Herceptin resistance (SK-BR-3
HR). In the present study we investigated whether
HSP27 phosphorylation inhibitor can reduce the resis-
tance of Herceptin by breaking interaction between
Her2 and HSP27 protein. HSP27 phosphorylation inhi-
bitor not only suppressed cell proliferation but also aug-
mented apoptotic cell death in both SK-BR-3 HR and
its parent cell line. Such anti-cancer effects were much
stronger in SK-BR-3 HR compared to its parent cell
line, and regulation of Her2 after HSP27 phosphoryla-
tion inhibitor treatment was found only in SK-BR-3 HR.
However, the interaction between HSP27 and Her2 was
not broken, but became increased by HSP27 phosphory-
lation inhibitor in a concentration dependent manner.
Overall results demonstrate that even HSP27 phosphor-
ylation inhibitor does not directly target the interaction
of HSP27 with Her2; it would be useful to alternative
option to overcome Herceptin resistance because it may
induce effective down-regulation of Her2.
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